A bis-sulphamoylated estradiol derivative induces ROS-dependent cell cycle abnormalities and subsequent apoptosis by Michelle Helen Visagie (3927308)

“…The effects of EMBS on H2A phosphorylation and nuclei were visualised using phospho H2A antibody and 4',6-diamidino-2-phenylindole, dihydrochloride. …”

Early correction of NMDAR function and NMDAR-dependent LTD by DCS treatment improves anxiolytic-like behavior, but not hypoactivity, in adult <i>Grin2b</i>^{<i>+/C456Y</i>}... by Wangyong Shin (6793040)

“…<i>n</i> = 9 cells from 4 mice for WT_V, 11 (5) for WT_D, 11 (5) for HT_V, 11 (3) for HT_D, *<i>P</i> < 0.05, two-way ANOVA with Tukey’s test. …”

Data_Sheet_1_Use of the word “evolution” in the time of a global pandemic.PDF by Sada M. Boyd (19238926)

β-diversity patterns are revealed with increasing sequencing depths between communities that differ only by random processes. by Ryoko Oono (4691824)

image5_Efficacy and Safety of Qishen Yiqi Dripping Pill for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.jpeg by Mengxi Wang (231051)

“…The “risk of bias” evaluation tool in the Cochrane Handbook was used to evaluate the quality of the included studies. RevMan 5.3 software was used for meta-analysis.</p><p>Results: Eight studies meeting the criteria were included, with a total of 895 patients. …”

Membrane-Integrated Glass Capillary Device for Preparing Small-Sized Water-in-Oil-in-Water Emulsion Droplets by Kazuki Akamatsu (1576882)

Membrane-Integrated Glass Capillary Device for Preparing Small-Sized Water-in-Oil-in-Water Emulsion Droplets by Kazuki Akamatsu (1576882)

Membrane-Integrated Glass Capillary Device for Preparing Small-Sized Water-in-Oil-in-Water Emulsion Droplets by Kazuki Akamatsu (1576882)

<i>Ramp2</i> is essential for proper spiral artery remodeling. by Mahita Kadmiel (4262311)

Raw data used for graph (related to Fig 1). by Mohammad Ali Baziyar (19353257)

“…It seems this drug was unable to reduce the expression of <i>MDM2</i> gene significantly in triple negative (MDA-MB-231) cancer cells; however, a decrease was observed in luminal A (MCF-7) cells. …”

Trajectories of a population of individuals with strategies for sex ratios of <i>0.2, 0.5</i> and <i>0.8</i> for initial conditions. by Krzysztof Argasinski (403756)

“…This mechanism is clearly shown in the trajectories of strategy <i>0.5</i>. The trajectory switches from a decrease to an increase when trajectory of passes the trajectory of (see panel <i>b</i>). …”

Table_5_Preoperative Fasting C-Peptide Acts as a Promising Predictor of Improved Glucose Tolerance in Patients With Acromegaly After Transsphenoidal Surgery: A Retrospective Study... by Zihao Wang (845023)

“…Afterwards, through Receiver operating characteristic (ROC) analyses, FCP >2.445 ng/ml was the best independent predictor, with an 86.6% PPV (positive predictive value) and a 74.5% NPV (negative predictive value).</p><p>Conclusions: Preoperative high FCP is a promising postsurgical predictor of improved glucose tolerance in patients with acromegaly. …”

Air Purifier Intervention to Remove Indoor PM_2.5 in Urban China: A Cost-Effectiveness and Health Inequality Impact Study by Ao Zhang (372387)

“…A high disparity in per capita health benefits and costs was observed by city, which expanded with the decrease of the indoor PM_2.5 target. …”

Air Purifier Intervention to Remove Indoor PM_2.5 in Urban China: A Cost-Effectiveness and Health Inequality Impact Study by Ao Zhang (372387)

“…A high disparity in per capita health benefits and costs was observed by city, which expanded with the decrease of the indoor PM_2.5 target. …”

Air Purifier Intervention to Remove Indoor PM_2.5 in Urban China: A Cost-Effectiveness and Health Inequality Impact Study by Ao Zhang (372387)

“…A high disparity in per capita health benefits and costs was observed by city, which expanded with the decrease of the indoor PM_2.5 target. …”

Primary and secondary outcomes of the randomized clinical trial groups at 3 months and 12 months. by Teemu P. Hevonkorpi (11577571)

Subjects:

Baseline characteristics of 291 patients by randomization group. by Teemu P. Hevonkorpi (11577571)

Subjects:

Adverse events at 12-month follow-up by study group. by Teemu P. Hevonkorpi (11577571)

Subjects:

Participant flow diagram of the DRIFT trial. by Teemu P. Hevonkorpi (11577571)

Subjects:

Between-group differences of mean PRWE with 95% confidence intervals in primarily malaligned DRFs and early malaligned DRFs at 3-month and 12-month follow-up. by Teemu P. Hevonkorpi (11577571)

Subjects: